Aberdeen Group plc Acquires New Position in Indivior PLC $INDV

Aberdeen Group plc acquired a new stake in Indivior PLC (NASDAQ:INDV) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 160,717 shares of the company’s stock, valued at approximately $3,875,000. Aberdeen Group plc owned 0.12% of Indivior as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in shares of Indivior by 1,122.6% during the 2nd quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock valued at $23,244,000 after acquiring an additional 1,447,939 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Indivior by 18.4% during the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after purchasing an additional 1,299,425 shares during the last quarter. Rubric Capital Management LP boosted its position in Indivior by 31.6% during the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock valued at $68,499,000 after purchasing an additional 1,117,140 shares during the last quarter. Jane Street Group LLC grew its stake in Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after purchasing an additional 958,132 shares in the last quarter. Finally, Acadian Asset Management LLC grew its stake in Indivior by 124.4% in the second quarter. Acadian Asset Management LLC now owns 1,492,272 shares of the company’s stock valued at $21,977,000 after purchasing an additional 827,230 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Insider Activity

In other news, Director Barbara Ryan purchased 775 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was bought at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director directly owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. The trade was a 65.24% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark Stejbach acquired 775 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the purchase, the director directly owned 16,847 shares of the company’s stock, valued at $596,215.33. This trade represents a 4.82% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 4,871 shares of company stock worth $172,385.

Analyst Ratings Changes

INDV has been the subject of several research reports. Northland Securities set a $50.00 price target on Indivior in a report on Tuesday, January 20th. Craig Hallum restated a “buy” rating and issued a $41.00 price objective on shares of Indivior in a report on Friday, October 31st. HC Wainwright raised their price objective on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Finally, Piper Sandler restated an “overweight” rating and set a $41.00 price target (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $39.33.

Indivior Stock Down 1.6%

NASDAQ:INDV opened at $33.89 on Friday. The company’s 50 day moving average is $34.77 and its 200-day moving average is $29.60. Indivior PLC has a 12 month low of $7.62 and a 12 month high of $38.00. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of 36.84 and a beta of 0.80.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.